Recently, Kobayashi et al. established EGFR-mutant lung cancer organoids using HCC827 and H1975 cells, incorporating mesenchymal stem cells and endothelial cells to investigate EGFR-tyrosine kinase inhibitor (TKI) resistance mechanisms in NSCLC [185]. This evidence concerns the gene EGFR and lung carcinoma.